Siewert J Rüdiger, Stein Hubert J, Feith Marcus
Chirurgische Klinik und Poliklinik der Technischen Universität München, Klinikum Rechts der Isar, Ismaningerstrasse 22, D-81675 München, Germany.
World J Surg. 2003 Sep;27(9):1058-61. doi: 10.1007/s00268-003-7061-1. Epub 2003 Aug 21.
Barrett's carcinoma, usually arising in the distal esophagus, must be considered a separate entity from squamous cell esophageal cancer. Epidemiology, etiology, patients' risk profiles, biology of metastases, and prognosis differ markedly between these two major esophageal tumor types. The preoperative work-up of patients with Barrett's cancer is primarily directed toward assessing the chances for R0 resection and estimating the risk of the patient to survive an esophagectomy. If R0 resection appears likely and the surgical risk is acceptable, the indication for an operative approach is given. From the oncologic point of view there is no difference between a radical transmediastinal approach and a transthoracic approach. A possible advantage of a transthoracic approach is the extension of lymphadenectomy to the upper mediastinum. Lymph node metastases in the upper mediastinum, however, usually indicate advanced lymphatic and subclinical systemic tumor dissemination, i.e., a poor prognosis even with extended surgery. Consequently the controversies about the surgical approach are reduced to technical and functional aspects. A better swallowing function argues for an intrathoracic anastomosis; the lower morbidity, for a cervical approach. We prefer transthoracic en bloc esophagectomy with an intrathoracic anastomosis in patients with moderate risk and early tumor stages. In all other patients radical transmediastinal esophagectomy with a cervical anastomosis is the procedure of choice. The overall 5-year survival rate of more than 40%, which is superior to most published data, supports this therapeutic strategy.
巴雷特食管癌通常发生在食管远端,必须被视为一种与食管鳞状细胞癌不同的独立疾病实体。这两种主要的食管肿瘤类型在流行病学、病因、患者风险特征、转移生物学及预后方面存在显著差异。巴雷特食管癌患者的术前检查主要旨在评估R0切除的可能性以及估计患者接受食管切除术后的生存风险。如果R0切除似乎可行且手术风险可接受,则可采取手术治疗。从肿瘤学角度来看,根治性经纵隔手术和经胸手术并无差异。经胸手术的一个可能优势是可将淋巴结清扫范围扩展至上纵隔。然而,上纵隔淋巴结转移通常提示存在广泛的淋巴转移及亚临床系统性肿瘤播散,即即便进行扩大手术预后也较差。因此,关于手术方式的争议已缩小至技术和功能方面。吞咽功能较好支持行胸内吻合;发病率较低则支持行颈部吻合。对于风险中等且肿瘤分期较早的患者,我们更倾向于行经胸整块食管切除并进行胸内吻合。对于所有其他患者,根治性经纵隔食管切除并进行颈部吻合是首选术式。超过40%的总体5年生存率高于大多数已发表的数据,这支持了这一治疗策略。